Quote | Sonnet BioTherapeutics Holdings Inc. (NASDAQ:SONN)
Last: | $0.88 |
---|---|
Change Percent: | -0.11% |
Open: | $0.931 |
Close: | $0.88 |
High: | $0.931 |
Low: | $0.8711 |
Volume: | 67,869 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
News | Sonnet BioTherapeutics Holdings Inc. (NASDAQ:SONN)
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 3.5% to $130.78 on volume of 504,910,586 shares Nikola Corporation (NKLA) fell 31.5% to $0.3296 on volume of 265,124,783 shares SMX (Security Matters) Public Limited Company (SMX) rose 35.1% to $0.1608 o...
PRINCETON, N.J., June 20, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the “Company” or “Sonnet”), a clinical-stage company developing targeted immunotherapeutic drugs, announced today the entry into a definitive agreement for the immed...
Message Board Posts | Sonnet BioTherapeutics Holdings Inc. (NASDAQ:SONN)
Subject | By | Source | When |
---|---|---|---|
WTF, is this an auction? I'll take.25s | Pnypnchr | investorshub | 06/28/2023 9:04:25 PM |
I love selected accounting myself.. $SONN | Carjockey2 | investorshub | 06/28/2023 7:58:53 PM |
Never see you posting on those stocks combined | Carjockey2 | investorshub | 06/28/2023 7:58:08 PM |
LMAO Not for me, it isn't sunshine... Funny how | Carjockey2 | investorshub | 06/28/2023 7:56:57 PM |
Off to where? 22% down. | jonestint | investorshub | 06/28/2023 7:53:27 PM |
News, Short Squeeze, Breakout and More Instantly...
Sonnet BioTherapeutics Holdings Inc. Company Name:
SONN Stock Symbol:
NASDAQ Market:
Sonnet BioTherapeutics Holdings Inc. Website:
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 3.5% to $130.78 on volume of 504,910,586 shares Nikola Corporation (NKLA) fell 31.5% to $0.3296 on volume of 265,124,783 shares SMX (Security Matters) Public Limited Company (SMX) rose 35.1% to $0.1608 o...
PRINCETON, N.J., June 20, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the “Company” or “Sonnet”), a clinical-stage company developing targeted immunotherapeutic drugs, announced today the entry into a definitive agreement for the immed...
Sonnet discovered and characterized a modified version of Interleukin-18 (IL-18 Binding Protein Resistant or IL-18 BPR ) that exhibits wild-type binding to the IL-18 receptor (IL-18Rc), coupled with undetectable binding to the inhibitory IL-18 Binding Protein (IL-18BP) ...